摘要
【目的】观察89SrCl2(二氯化89锶)联合99Tc-MDP(云克)治疗多发性骨转移癌的近期疗效和安全性。【方法】48例各种肿瘤伴骨转移的病人,随机分为A组即使用放射性核素89SrCl2联合云克治疗和B组即单独使用89SrCl2治疗,并追踪观察疗效。【结果】A组有效率为95.83%(23/24);B组有效率75.00%(18/24),A组有效率高于B组,差异有显著性(P<0.05)。两组骨髓抑制作用无明显差异(P>0.05)。【结论】89SrCl2联合“云克”治疗比单独应用89SrCl2治疗多发性骨转移癌效果好8。9SrCl2联合“云克”有相互协同作用,无明显副作用。个别病人血象降低明显,应予以高度重视。
[Objective]To observe the therapeutic effectiveness of ^99Sr and Yunke on the skeletal metastases. [Methods] Forty eight patients with bone metastases from various primaries were randomly treated with ^89Sr combined with ＂Yunke＂（^99Tc-MDP） （A group） and ^89Sr （B group）. The effect of relieving pain and negative responses were observed. [Results]The effect rate of A group was 95.83%（23/24）. The effect rate of B group was 75.00%（18/24） . The effect rate of A was higher than that of the B group （ P〈0.05）, The major toxicity was bone marrow suppression in both groups no difference, between them. （ P〉0. 05）. [Conclusion] The therap of ＂^89Sr＂and ＂Yunke＂ on skeletal metastases can relieve pain for long term. ^89Sr cooperated with ＂ Yunke＂ to treat skeletal metastases has a few side effects, The blood routine tests of a few patients treated with ＂^89Sr＂and ＂Yunke＂ are obviously reduced , which should be paid attention to.
出处
《医学临床研究》
CAS
2006年第8期1232-1233,1236,共3页
Journal of Clinical Research
